These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 17020781

  • 1. Effects of higenamine and its 1-naphthyl analogs, YS-49 and YS-51, on platelet TXA2 synthesis and aggregation.
    Pyo MK, Kim JM, Jin JL, Chang KC, Lee DH, Yun-Choi HS.
    Thromb Res; 2007; 120(1):81-6. PubMed ID: 17020781
    [Abstract] [Full Text] [Related]

  • 2. Antiplatelet activity of carnosol is mediated by the inhibition of TXA2 receptor and cytosolic calcium mobilization.
    Lee JJ, Jin YR, Lim Y, Hong JT, Kim TJ, Chung JH, Yun YP.
    Vascul Pharmacol; 2006 Sep; 45(3):148-53. PubMed ID: 16916624
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Antithrombotic effects of YS-49 and YS-51--1-naphthylmethyl analogs of higenamine.
    Yun-Choi HS, Pyo MK, Park KM, Chang KC, Lee DH.
    Thromb Res; 2001 Nov 15; 104(4):249-55. PubMed ID: 11728526
    [Abstract] [Full Text] [Related]

  • 5. Antiplatelet activity of J78 (2-Chloro-3-[2'-bromo, 4'-fluoro-phenyl]-amino-8-hydroxy-1,4-naphthoquinone), an antithrombotic agent, is mediated by thromboxane (TX) A2 receptor blockade with TXA2 synthase inhibition and suppression of cytosolic Ca2+ mobilization.
    Jin YR, Cho MR, Ryu CK, Chung JH, Yuk DY, Hong JT, Lee KS, Lee JJ, Lee MY, Lim Y, Yun YP.
    J Pharmacol Exp Ther; 2005 Jan 15; 312(1):214-9. PubMed ID: 15328379
    [Abstract] [Full Text] [Related]

  • 6. I4, a new synthetic sulfonylurea compound, inhibits the action of TXA2 in vivo and in vitro on platelets and aorta vascular smooth muscle.
    Lu N, Zhan M, Gao C, Wu G, Zhang H.
    Thromb Res; 2012 Oct 15; 130(4):e209-15. PubMed ID: 22909828
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacological characterization of 2NTX-99 [4-methoxy-N1-(4-trans-nitrooxycyclohexyl)-N3-(3-pyridinylmethyl)-1,3-benzenedicarboxamide], a potential antiatherothrombotic agent with antithromboxane and nitric oxide donor activity in platelet and vascular preparations.
    Buccellati C, Sala A, Rossoni G, Capra V, Rovati GE, Di Gennaro A, Folco G, Colli S, Casagrande C.
    J Pharmacol Exp Ther; 2006 May 15; 317(2):830-7. PubMed ID: 16399881
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Alteration of release and role of adenosine diphosphate and thromboxane A2 during collagen-induced aggregation of platelets from cattle with Chediak-Higashi syndrome.
    Honda N, Ohnishi K, Fujishiro T, Ikeda M, Ito K.
    Am J Vet Res; 2007 Dec 15; 68(12):1399-406. PubMed ID: 18052747
    [Abstract] [Full Text] [Related]

  • 11. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
    Hanson J, Rolin S, Reynaud D, Qiao N, Kelley LP, Reid HM, Valentin F, Tippins J, Kinsella BT, Masereel B, Pace-Asciak C, Pirotte B, Dogné JM.
    J Pharmacol Exp Ther; 2005 Apr 15; 313(1):293-301. PubMed ID: 15626721
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Inhibition of oxidative-stress-induced platelet aggregation by androgen at physiological levels via its receptor is associated with the reduction of thromboxane A2 release from platelets.
    Li S, Li X, Li J, Deng X, Li Y.
    Steroids; 2007 Nov 15; 72(13):875-80. PubMed ID: 17825336
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets.
    Jin YR, Cho MR, Lee KS, Lee JJ, Lim Y, Han XH, Oh KW, Hong JT, Yoo HS, Yun YP.
    Basic Clin Pharmacol Toxicol; 2005 Sep 15; 97(3):162-7. PubMed ID: 16128910
    [Abstract] [Full Text] [Related]

  • 18. Enantioselective synthesis of (R)-(+)- and (S)-(-)-higenamine and their analogues with effects on platelet aggregation and experimental animal model of disseminated intravascular coagulation.
    Pyo MK, Lee DH, Kim DH, Lee JH, Moon JC, Chang KC, Yun-Choi HS.
    Bioorg Med Chem Lett; 2008 Jul 15; 18(14):4110-4. PubMed ID: 18556200
    [Abstract] [Full Text] [Related]

  • 19. Pathogenetic analysis of five cases with a platelet disorder characterized by the absence of thromboxane A2 (TXA2)-induced platelet aggregation in spite of normal TXA2 binding activity.
    Fuse I, Hattori A, Mito M, Higuchi W, Yahata K, Shibata A, Aizawa Y.
    Thromb Haemost; 1996 Dec 15; 76(6):1080-5. PubMed ID: 8972034
    [Abstract] [Full Text] [Related]

  • 20. Antiplatelet effect of NQ12: a possible mechanism through the arachidonic acid cascade.
    Jin YR, Han XH, Lee JJ, Lim Y, Kim TJ, Yoo HS, Hong JT, Lee CK, Yun YP.
    J Pharmacol Sci; 2007 Oct 15; 105(2):193-200. PubMed ID: 17951980
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.